Intersect ENT, Inc. provided revenue guidance for the first quarter of 2020. For the quarter, the company expects net sales to be in the range of $19.5 to $19.8 million, compared to $26.7 million in the first quarter of 2019.

Due to the rapidly evolving environment and continued uncertainties resulting from the impact of COVID-19, the Company is withdrawing its previously announced annual guidance for 2020, which was issued on February 24, 2020. At this date, the Company cannot predict the extent or duration of the impact of the COVID-19 pandemic on its financial and operating results, but believes current government policies, including the suspension of elective procedures worldwide, will substantially impact its revenues in the second quarter of 2020 and potentially longer. While the financial impact will certainly impact near term results, the Company believes the actions it has taken will enable it to maintain its ability to return to growth as the current crisis subsides.